Lux Capital’s Larry Bock and Josh Wolfe Warm to Venture Deals Despite Nuclear Winter

 well beyond nanotechnology. He explained that Lux closed its second venture fund at $100 million in January. About a third of Lux Ventures II has been invested so far in 12 companies that are developing innovations mostly in the life sciences and physical science, especially in energy, communications, and semiconductors.

Josh Wolfe
Josh Wolfe

“We have a contrarian view on energy,” said Wolfe, who contends nuclear energy is badly needed and under-utilized. “One area where we’ve focused involves one of the biggest problems we have to solve, which is the treatment or remediation of nuclear waste.”

Wolfe says the wave of venture interest in cleantech and renewable energy investments gives him “pause.” He views investing in algae-based energy startups as a step in the wrong direction because energy technology development has “always gone to denser and denser fuels.” To Wolfe, developing algae biofuels requires “going back to an agrarian economy… I think the jury is out whether the market will reward a biotech product that is basically a commodity.”

But Bock, who is a seed investor in San Diego biofuels developer Sapphire Energy, said he’s more optimistic. “I’m excited about it because they’ve very quickly gone from pure concept to actually doing it. They were flying commercial airliners on algae-based jet fuels in January.”

Finally, I asked Bock and Wolfe about the recent decline of venture capital investing, a nationwide trend that was acute in San Diego during the first three months of 2009.

“I think it’s safe to say that many VC firms are populated by senior partners who will say, ‘We created some great companies and made money for our limited partners, and now it’s time to retire,’ ” Wolfe said. He nevertheless says this is a great opportunity for venture investing, with markets low and a lot of expert talent now available that previously might have been too expensive to hire.

Bock agreed, saying, “I was most successful in biotechnology during the last nuclear winter in the early 1990s. I’ve seen this cycle in biotechnology several times during my career. I don’t think venture capital is dead and I don’t think the model is broken…In terms of early-stage investing in technologies coming out of universities, it’s like being a kid in a candy store.”

Author: Bruce V. Bigelow

In Memoriam: Our dear friend Bruce V. Bigelow passed away on June 29, 2018. He was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Bruce Bigelow joined Xconomy from the business desk of the San Diego Union-Tribune. He was a member of the team of reporters who were awarded the 2006 Pulitzer Prize in National Reporting for uncovering bribes paid to San Diego Republican Rep. Randy “Duke” Cunningham in exchange for special legislation earmarks. He also shared a 2006 award for enterprise reporting from the Society of Business Editors and Writers for “In Harm’s Way,” an article about the extraordinary casualty rate among employees working in Iraq for San Diego’s Titan Corp. He has written extensively about the 2002 corporate accounting scandal at software goliath Peregrine Systems. He also was a Gerald Loeb Award finalist and National Headline Award winner for “The Toymaker,” a 14-part chronicle of a San Diego start-up company. He takes special satisfaction, though, that the series was included in the library for nonfiction narrative journalism at the Nieman Foundation for Journalism at Harvard University. Bigelow graduated from U.C. Berkeley in 1977 with a degree in English Literature and from the Columbia University Graduate School of Journalism in 1979. Before joining the Union-Tribune in 1990, he worked for the Associated Press in Los Angeles and The Kansas City Times.